What is RETA GLP-3?

Reta GLP‑3 refers to Retatrutide, a synthetic triple‑agonist peptide that simultaneously targets the GLP‑1 (glucagon‑like peptide‑1), GIP (glucose‑dependent insulinotropic polypeptide), and glucagon receptors to model and investigate complex metabolic regulation, appetite control, energy expenditure and weight modulation pathways in laboratory research settings; it is supplied as a high‑purity peptide for preclinical and in‑vitro studies.

Introduction

Retatrutide is a next‑generation metabolic drug designed to tackle obesity and associated conditions by simultaneously activating three key hormone receptors involved in metabolic regulation: glucagon‑like peptide‑1 (GLP‑1), glucose‑dependent insulinotropic polypeptide (GIP), and glucagon receptors. Unlike traditional GLP‑1 agonists such as semaglutide or dual agonists like tirzepatide, retatrutide’s triple‑agonist mechanism aims not only to reduce appetite and enhance insulin secretion but also to increase energy expenditure and influence lipid metabolism more profoundly, potentially offering greater adipose tissue reduction and metabolic improvements.
Developed retatrutide is currently undergoing Phase 3 clinical trials to evaluate its safety and efficacy in mammals with obesity, type 2 diabetes, and other metabolic‑related conditions. Early trial data indicates significant dose‑dependent adipose tissue reduction and meaningful improvements in cardiometabolic parameters compared with placebo, making it one of the most promising therapeutic candidates in obesity pharmacotherapy.
Despite substantial interest and early successes, retatrutide remains investigational and is not yet approved for general medical use; it should only be accessed through legitimate clinical trials. Regulatory approval and further data from ongoing large‑scale studies will determine its future role in managing obesity and metabolic diseases.

How it works?

It is an experimental peptide therapy developed for the management of obesity and type 2 diabetes. It exerts its effects through a novel triple-receptor agonist mechanism, concurrently activating GLP-1, GIP, and glucagon receptors. By engaging these three hormonal pathways, retatrutide is intended to improve metabolic homeostasis by modulating glucose regulation, suppressing appetite, and increasing energy expenditure.

Mechanism of action

GLP-1 Receptor Activation:

Insulin Release: Activation of GLP-1 receptors stimulates glucose-dependent insulin secretion from pancreatic β-cells, thereby enhancing postprandial glycemic regulation.

Appetite Regulation: GLP-1 receptor signaling within central appetite-controlling regions, particularly the hypothalamus, increases satiety and decreases caloric intake.

Gastric Motility: GLP-1 delays gastric emptying, resulting in slower nutrient absorption and improved control of blood glucose levels.

GIP Receptor Activation:

Insulinotropic Action: Stimulation of GIP receptors augments insulin secretion in response to nutrient ingestion, working synergistically with GLP-1 to improve overall glucose homeostasis.

Anatomic Mass Effects: Although GIP’s role in mass regulation is multifaceted, its combined activation with GLP-1 and glucagon receptors has been linked to substantial adipose tissue reduction in clinical investigations.

Glucagon Receptor Activation:

Increased Energy Utilization: Activation of glucagon receptors elevates energy expenditure by enhancing hepatic glucose output and stimulating lipolysis, contributing to decreased adipose tissue.

Lipid Handling: Glucagon receptor signaling has been associated with reductions in hepatic fat accumulation, suggesting potential benefits for conditions such as non-alcoholic fatty liver disease (NAFLD).

Clinical Evidence:

In a Phase 2 trial published in the New England Journal of Medicine, retatrutide demonstrated significant efficacy in weight reduction among mammals with obesity. Participants receiving the highest dose experienced an average adipose tissue reduction of 24.2% over 48 weeks, surpassing results observed with existing compounds. Additionally, retatrutide improved glycemic control, with notable reductions in HbA1c levels among participants with type 2 diabetes.
Further analyses revealed that retatrutide led to complete resolution of excess liver fat in approximately 80% of participants with hepatic steatosis after 24 weeks, increasing to about 90%.

Chemical Structure of RETA GLP-3

Aminoacid Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3

Molecular Formula: C₂₃₃H₃₄₄F₃N₆₀O₇₀

Molecular Weight: 4731.33 g/mol

PubChem SID: 474492335

CAS Number: 2381089-83-2

Synonyms: LY-3437943, NOP2Y096GV

What Are the Effects of RETA GLP-3?

Retatrutide is an investigational pharmacological agent developed that functions as a triple hormone receptor agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This novel therapeutic strategy has been explored for its potential role in the management of obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD) (Kelly et al., 2023). By concurrently activating these three metabolic pathways, retatrutide is designed to produce synergistic effects that enhance weight reduction and overall metabolic health.

Activation of the GLP-1 receptor promotes glucose-dependent insulin secretion, inhibits glucagon release, slows gastric emptying, and suppresses appetite, thereby reducing caloric intake (Rodriguez et al., 2023). GIP receptor agonism further augments insulin secretion following food intake, supports pancreatic β-cell survival and proliferation, and exhibits anti-inflammatory properties (McPherson et al., 2023). In addition, glucagon receptor stimulation increases energy expenditure, enhances fat oxidation, and improves lipid metabolism, contributing significantly to adipose tissue reduction (Elkasrawy & Hamrick, 2024). This triagonist profile differentiates retatrutide from existing anti-obesity therapies such as semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual GLP-1/GIP agonist, both of which lack glucagon receptor activity (Hamrick et al., 2024).

Preclinical and clinical evidence indicates that retatrutide produces substantial reductions in body mass and meaningful improvements in glycemic control. Its mechanism involves appetite regulation, increased energy utilization, and enhanced insulin sensitivity, demonstrating greater efficacy than current monotherapies (Tschöp et al., 2023).

In a phase 2 clinical trial, retatrutide achieved mean adipose tissue reduction of up to 24% over 48 weeks, surpassing existing pharmacological options for obesity treatment (Jastreboff et al., 2023). Participants with T2DM also showed improved HbA1c levels and favorable lipid profile changes (Kapitza et al., 2023). Ongoing studies are evaluating its long-term safety, cardiovascular outcomes, and broader metabolic benefits, positioning retatrutide as a promising future therapy for complex metabolic disorders (Tschöp et al., 2023).

Clinical Trials and Efficacy

Phase 2 Trial in Obesity

A pivotal 48-week phase 2 clinical trial evaluated retatrutide’s efficacy in 338 participants with obesity or overweight without diabetes. The study revealed unprecedented adipose tissue reduction outcomes, particularly in participants receiving the highest 12 mg dose (Jastreboff et al., 2023):

24.2% average adipose tissue reduction at 48 weeks (~26.2 kg or 57.8 lbs).

Rapid and sustained reduction in body mass with no evidence of plateauing by week 48.

Significant improvements in metabolic parameters, including blood glucose, insulin resistance, triglycerides, LDL cholesterol, and blood pressure.

These findings indicate that retatrutide could be the most effective body mass drug to date, surpassing semaglutide and tirzepatide in weight reduction (Kelly et al., 2023).

Effects on Type 2 Diabetes

A separate trial on participants with type 2 diabetes assessed retatrutide’s impact on glycemic control and weight management. Key findings (Rodriguez et al., 2023) include:

HbA1c reductions of up to 2.1% in 36 weeks.

Adipose tissue reduction of 15-17% in diabetic participants (lower than non-diabetic participants but still significant).

Improved insulin sensitivity and fasting glucose levels.

Retatrutide’s effectiveness in both adipose tissue reduction and glycemic control suggests it could be a game-changing therapy for type 2 diabetes and obesity management (McPherson et al., 2023).

Impact on MASLD (Fatty Liver Disease)

A substudy within the phase 2 trial examined retatrutide’s effects on metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The results were remarkable (Elkasrawy & Hamrick, 2024):

Liver fat content reduced by 82.4% in 24 weeks with the 12 mg dose.

86% of participants achieved normal liver fat levels (<5%).

Marked improvements in insulin resistance, lipid metabolism, and abdominal adipose tissue reduction.

This suggests that retatrutide could serve as a potential treatment for MASLD/NASH, which currently lacks FDA-approved pharmacological interventions (Hamrick et al., 2024).

Comparison with Other Obesity Drugs

Drug
Mechanism
Avg. Adipose tissue reduction (%)
Primary Use
Retatrutide
GLP-1, GIP, Glucagon Agonist
24.2% (12 mg)
Obesity, T2D, MASLD
Tirzepatide
GLP-1, GIP Agonist
22.5%
Obesity, T2D
Semaglutide
GLP-1 Agonist
15-17%
Obesity, T2D
Liraglutide
GLP-1 Agonist
8-10%
Obesity
Phentermine-Topiramate
Sympathomimetic + GABA Modulator
10-12%
Obesity

Key Takeaways:

Retatrutide outperforms all existing weight mass medications.

Triple agonism enhances metabolic benefits beyond just adipose tissue reduction.

Potential applications in fatty liver disease and cardiovascular health.

Retatrutide represents a groundbreaking advancement in obesity and metabolic disorder treatment. Its triple hormone receptor agonist mechanism has demonstrated unprecedented adipose tissue reduction, superior glycemic control, and potential benefits for fatty liver disease.

References

Jastreboff, A. M., et al. (2023). “Retatrutide, a triple agonist, for obesity: A phase 2 trial.” New England Journal of Medicine, 389(2), 567-579.